Australia markets closed

Boston Scientific Corporation (BSX)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
39.54+1.61 (+4.24%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close37.93
Open38.36
Bid0.00 x 1000
Ask0.00 x 2900
Day's range38.22 - 39.71
52-week range24.10 - 42.37
Volume12,809,414
Avg. volume11,020,521
Market cap55.997B
Beta (5Y monthly)N/A
PE ratio (TTM)15.18
EPS (TTM)N/A
Earnings date27 Apr 2021 - 03 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est43.36
  • Boston Scientific (BSX) Down 2.1% Since Last Earnings Report: Can It Rebound?
    Zacks

    Boston Scientific (BSX) Down 2.1% Since Last Earnings Report: Can It Rebound?

    Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Boston Scientific (BSX) Buys Lumenis to Expand in Urology
    Zacks

    Boston Scientific (BSX) Buys Lumenis to Expand in Urology

    The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.

  • Boston Scientific Announces Agreement To Acquire Lumenis LTD. Surgical Business From Baring Private Equity Asia
    PR Newswire

    Boston Scientific Announces Agreement To Acquire Lumenis LTD. Surgical Business From Baring Private Equity Asia

    Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of $1.07 billion, subject to closing adjustments. BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. With 2021 net sales anticipated to be approximately $200 million, the Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures. Foundational to its urology portfolio is the proprietary MOSES™ technology, which has demonstrated differentiated clinical outcomes and efficiency in the management of patients with kidney stones.